Insider Buying: Veru Inc. (NASDAQ:VERU) Director Acquires 95,279 Shares of Stock

Veru Inc. (NASDAQ:VERU) Director Michael L. Rankowitz purchased 95,279 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average price of $0.55 per share, with a total value of $52,403.45. Following the purchase, the director now owns 195,279 shares in the company, valued at $107,403.45. This represents a 95.28 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Veru Price Performance

VERU stock traded down $0.01 during trading on Thursday, hitting $0.59. The stock had a trading volume of 1,077,020 shares, compared to its average volume of 4,952,698. The company’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $0.76. Veru Inc. has a twelve month low of $0.47 and a twelve month high of $1.92. The stock has a market capitalization of $86.22 million, a P/E ratio of -2.27 and a beta of -0.54.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Thursday, February 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. As a group, sell-side analysts expect that Veru Inc. will post -0.22 EPS for the current fiscal year.

Analysts Set New Price Targets

VERU has been the subject of a number of recent analyst reports. Oppenheimer restated an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Veru in a report on Thursday, January 2nd.

Institutional Investors Weigh In On Veru

Several institutional investors and hedge funds have recently added to or reduced their stakes in VERU. SG Americas Securities LLC raised its position in shares of Veru by 185.9% in the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock valued at $51,000 after buying an additional 42,997 shares during the last quarter. Gladstone Institutional Advisory LLC grew its stake in Veru by 34.2% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after acquiring an additional 14,500 shares in the last quarter. State Street Corp raised its holdings in Veru by 4.3% in the 3rd quarter. State Street Corp now owns 2,072,065 shares of the company’s stock valued at $1,593,000 after acquiring an additional 84,483 shares during the last quarter. Jane Street Group LLC lifted its stake in Veru by 142.8% in the 3rd quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock worth $74,000 after purchasing an additional 56,736 shares in the last quarter. Finally, Zacks Investment Management purchased a new position in Veru in the 3rd quarter worth approximately $25,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.